This story has been updated to include additional information about genome coverage of Twist's SARS-CoV-2 sequencing panel.
NEW YORK – Twist Bioscience revealed Thursday that it has been expanding its targeted next-generation sequencing products by developing genotyping panels for pharmaceutical firm Regeneron as well as minimal residual disease testing assays.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
